Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078707989> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2078707989 endingPage "544" @default.
- W2078707989 startingPage "540" @default.
- W2078707989 abstract "Stage IV melanoma has a poor prognosis with a median survival of 3-11 months from diagnosis of distant metastases. Response rates in first-line regimens range around 15-20%. Non-responders have a median survival around 6 months. Currently, no second-line treatment in advanced melanoma has been established.In a clinical phase II study we evaluated the efficacy of liposomal doxorubicin (Caelyx) in 30 patients (17 m, 13 f) with progressing metastatic melanoma who had failed a previous chemotherapy. Liposomal doxorubicin was given in an outpatient setting at a dose of 50 mg/m2 i.v. on d1, d22, d43 and d64, subsequently at 40 mg/m2 at d85 before first staging and in 4-week intervals thereafter. Treatment was very well tolerated with 100 cycles given in total. Response rate, survival time, time-to-progression and toxicity were assessed.Erythrodysesthesia was the most severe toxicity in 6% at CTC grade 3. Liposomal doxorubicin was of limited clinical efficacy with 21 patients progressing within the first 12 weeks. However, 7 patients were treated 3-9 months and were stable for >90 days, achieving 5 SD, 1 PR and 1 CR. Median survival after initiation of second-line treatment was 214 days (95% CI: 151-304 days) with 7 patients surviving >300 and 5 patients >400 days.Liposomal doxorubin as monotherapy is well tolerated but of limited clinical efficacy. Whether the survival benefit of a significant proportion of patients (20%) holds true in larger cohorts and whether the efficacy of liposomal doxorubicin can be improved by combinations without compromising the low toxicity profile needs further studies." @default.
- W2078707989 created "2016-06-24" @default.
- W2078707989 creator A5019834532 @default.
- W2078707989 creator A5025861566 @default.
- W2078707989 creator A5034365278 @default.
- W2078707989 creator A5040072566 @default.
- W2078707989 creator A5057381405 @default.
- W2078707989 creator A5082960985 @default.
- W2078707989 creator A5090872399 @default.
- W2078707989 date "2004-01-01" @default.
- W2078707989 modified "2023-09-26" @default.
- W2078707989 title "Clinical Phase II Study of Pegylated Liposomal Doxorubicin as Second-Line Treatment in Disseminated Melanoma" @default.
- W2078707989 cites W1967157358 @default.
- W2078707989 cites W1989594290 @default.
- W2078707989 cites W1993455773 @default.
- W2078707989 cites W2036531257 @default.
- W2078707989 cites W2097157431 @default.
- W2078707989 cites W2160479880 @default.
- W2078707989 cites W2318443590 @default.
- W2078707989 doi "https://doi.org/10.1159/000081335" @default.
- W2078707989 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15591712" @default.
- W2078707989 hasPublicationYear "2004" @default.
- W2078707989 type Work @default.
- W2078707989 sameAs 2078707989 @default.
- W2078707989 citedByCount "19" @default.
- W2078707989 countsByYear W20787079892015 @default.
- W2078707989 countsByYear W20787079892016 @default.
- W2078707989 countsByYear W20787079892020 @default.
- W2078707989 countsByYear W20787079892021 @default.
- W2078707989 countsByYear W20787079892022 @default.
- W2078707989 crossrefType "journal-article" @default.
- W2078707989 hasAuthorship W2078707989A5019834532 @default.
- W2078707989 hasAuthorship W2078707989A5025861566 @default.
- W2078707989 hasAuthorship W2078707989A5034365278 @default.
- W2078707989 hasAuthorship W2078707989A5040072566 @default.
- W2078707989 hasAuthorship W2078707989A5057381405 @default.
- W2078707989 hasAuthorship W2078707989A5082960985 @default.
- W2078707989 hasAuthorship W2078707989A5090872399 @default.
- W2078707989 hasConcept C126322002 @default.
- W2078707989 hasConcept C141071460 @default.
- W2078707989 hasConcept C143998085 @default.
- W2078707989 hasConcept C2776694085 @default.
- W2078707989 hasConcept C2777658100 @default.
- W2078707989 hasConcept C2781303535 @default.
- W2078707989 hasConcept C29730261 @default.
- W2078707989 hasConcept C31760486 @default.
- W2078707989 hasConcept C502942594 @default.
- W2078707989 hasConcept C71924100 @default.
- W2078707989 hasConcept C90924648 @default.
- W2078707989 hasConceptScore W2078707989C126322002 @default.
- W2078707989 hasConceptScore W2078707989C141071460 @default.
- W2078707989 hasConceptScore W2078707989C143998085 @default.
- W2078707989 hasConceptScore W2078707989C2776694085 @default.
- W2078707989 hasConceptScore W2078707989C2777658100 @default.
- W2078707989 hasConceptScore W2078707989C2781303535 @default.
- W2078707989 hasConceptScore W2078707989C29730261 @default.
- W2078707989 hasConceptScore W2078707989C31760486 @default.
- W2078707989 hasConceptScore W2078707989C502942594 @default.
- W2078707989 hasConceptScore W2078707989C71924100 @default.
- W2078707989 hasConceptScore W2078707989C90924648 @default.
- W2078707989 hasIssue "6" @default.
- W2078707989 hasLocation W20787079891 @default.
- W2078707989 hasLocation W20787079892 @default.
- W2078707989 hasOpenAccess W2078707989 @default.
- W2078707989 hasPrimaryLocation W20787079891 @default.
- W2078707989 hasRelatedWork W2024219304 @default.
- W2078707989 hasRelatedWork W2047967234 @default.
- W2078707989 hasRelatedWork W2054942282 @default.
- W2078707989 hasRelatedWork W2100029565 @default.
- W2078707989 hasRelatedWork W2411435305 @default.
- W2078707989 hasRelatedWork W2419299658 @default.
- W2078707989 hasRelatedWork W2439875401 @default.
- W2078707989 hasRelatedWork W2917681345 @default.
- W2078707989 hasRelatedWork W3203829896 @default.
- W2078707989 hasRelatedWork W4306163962 @default.
- W2078707989 hasVolume "27" @default.
- W2078707989 isParatext "false" @default.
- W2078707989 isRetracted "false" @default.
- W2078707989 magId "2078707989" @default.
- W2078707989 workType "article" @default.